- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06741228
Een fase 3 dubbelblinde, placebogecontroleerde studie (deel A) met een open-label extensie (deel B) Evaluatie van MM120 vergeleken met placebo bij gegeneraliseerde angststoornis
Een fase 3, multicenter, gerandomiseerde, dubbelblinde, placebogecontroleerde, 12 weken durende studie (deel A) met een open-label verlenging van 40 weken (deel B) Evaluatie van de werkzaamheid en veiligheid van orale MM120 vergeleken met placebo in de Behandeling van volwassenen met gegeneraliseerde angststoornis - Reis
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.
The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Gilbert, Arizona, Verenigde Staten, 85234
- Lighthouse Psychiatry
-
Scottsdale, Arizona, Verenigde Staten, 85022
- Scottsdale Research Institute
-
-
California
-
La Jolla, California, Verenigde Staten, 92037
- Kadima Neuropsychiatry Institute
-
San Francisco, California, Verenigde Staten, 94158
- UCSF Department of Neurology
-
Santa Monica, California, Verenigde Staten, 90404
- Psychedelic Science Institute
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80209
- Mountain View
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32256
- Clinical Neuroscience Solutions Inc.
-
Lauderhill, Florida, Verenigde Staten, 33319
- Segal Trials
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30331
- Atlanta Center for Medical Research
-
Decatur, Georgia, Verenigde Staten, 30030
- iResearch Atlanta
-
Savannah, Georgia, Verenigde Staten, 31405
- CenExel iResearch, LLC
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60640
- Uptown Research Institute
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02116
- Adams Clinical Boston
-
Watertown, Massachusetts, Verenigde Staten, 02472
- Adams Clinical Watertown
-
-
New Jersey
-
Marlton, New Jersey, Verenigde Staten, 08053
- Hassman Research Institute
-
-
New York
-
New York, New York, Verenigde Staten, 10021
- Spectrum Neuroscience and Treatment Institute
-
New York, New York, Verenigde Staten, 10032
- New York State Psychiatric Institute (NYSPI)
-
New York, New York, Verenigde Staten, 10029
- Adams Clinical Harlem
-
The Bronx, New York, Verenigde Staten, 10461
- Adams Clinical Bronx
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44113
- Cleveland Clinic Lutheran Hospital
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
- Summit Headlands LLC
-
-
Pennsylvania
-
Moosic, Pennsylvania, Verenigde Staten, 18507
- Scranton Medical Institute
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Adams Clinical Philadelphia
-
-
South Carolina
-
North Charleston, South Carolina, Verenigde Staten, 29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38119
- Clinical Neuroscience Solutions, Inc.
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78712
- University of Texas at Austin
-
Austin, Texas, Verenigde Staten, 78759
- BioBehavioral Research of Austin
-
Austin, Texas, Verenigde Staten, 78737
- Austin Clinical Trial Partners
-
Dallas, Texas, Verenigde Staten, 75231
- FutureSearch Trials of Dallas, LLC
-
DeSoto, Texas, Verenigde Staten, 75115
- Adams Clinical Dallas
-
-
Utah
-
Draper, Utah, Verenigde Staten, 84020
- Cedar Clinical Research
-
Orem, Utah, Verenigde Staten, 84058
- Inner Space Research
-
-
Vermont
-
Bennington, Vermont, Verenigde Staten, 05201
- Memory Clinic Inc.
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98104
- Seattle Neuropsychiatric Treatment Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of GAD per DSM-5
- Male or female aged 18 to 74
- HAM-A Total Score ≥20
Exclusion Criteria:
- Certain psychiatric disorders (other than generalized anxiety disorder)
- First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
- Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
- Any clinically significant unstable illness
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Arm 1 - Placebo
A substance that is designed to have no therapeutic value |
A substance that is designed to have no therapeutic value |
|
Experimenteel: Arm 2 - 100µg DT120
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A) |
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
Tijdsspanne: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period
Tijdsspanne: Day 2 to Week 12
|
The CGI-I scale is used to measure the clinician's assessment of how much the participant's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises one item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. |
Day 2 to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Tijdsspanne: Baseline to Week 12
|
The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Tijdsspanne: Baseline to Week 12
|
The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)
Tijdsspanne: Baseline to Week 12
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). |
Baseline to Week 12
|
|
Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period
Tijdsspanne: Baseline to Week 12
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
Baseline to Week 12
|
|
Percent of men and women with normal and abnormal sexual functioning at each timepoint assessed during the double-blind period
Tijdsspanne: Baseline to Week 12
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
Baseline to Week 12
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in MADRS total score
Tijdsspanne: Baseline to Week 52
|
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Tijdsspanne: Baseline to Week 52
|
The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Tijdsspanne: Baseline to Week 52
|
The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in WPAI-SHP
Tijdsspanne: Baseline to Week 52
|
The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in EQ-5D-5L
Tijdsspanne: Baseline to Week 52
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). |
Baseline to Week 52
|
|
Percent men and women with normal and abnormal sexual functioning at each timepoint assessed during the open-label period
Tijdsspanne: 40 week open label period
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
40 week open label period
|
|
Change from Baseline in HAM-A total score at Week 8, Week 4, Week 2, and Week 1
Tijdsspanne: Week 8, Week 4, Week 2, and Week 1
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Week 8, Week 4, Week 2, and Week 1
|
|
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
Tijdsspanne: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
|
HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period
Tijdsspanne: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Tijdsspanne: Baseline to Week 12
|
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)
Tijdsspanne: Baseline to Week 12
|
The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study. |
Baseline to Week 12
|
|
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period
Tijdsspanne: Day 1 to Week 52
|
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period |
Day 1 to Week 52
|
|
Time to first treatment or lack of efficacy in the open-label period (Part B)
Tijdsspanne: Day 1 to Week 52
|
Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy |
Day 1 to Week 52
|
|
Need for DT120 treatment as assessed by the average number of DT120 treatments during the study
Tijdsspanne: Day 1 to Week 52
|
Average number of treatments assessed from first dose in the double-blind period through completion of the open label extension. |
Day 1 to Week 52
|
|
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period
Tijdsspanne: 40 week open label period
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
40 week open label period
|
|
HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period
Tijdsspanne: 40 week open label period
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
40 week open label period
|
|
CSFQ-14 total score at each timepoint assessed during the open-label period
Tijdsspanne: 40 week open label period
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
40 week open label period
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MM120-300
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .